Analyst consensus rating
Starling Oncology Analyst Rating: none
STLN is rated none by 5 analysts with a $9.00 target. As of 2026-08-27.
Direct answer
Starling Oncology's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.00.
Forecast evidence checked August 27, 2026.
Get free Starling Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.56
- Average price target
- $9.00
- High price target
- $11.00
- Low price target
- $7.00
- Low target gap
- +6.7%
- Target upside
- +37.2%
- High target gap
- +67.7%
- Target range width
- 61%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Starling Oncology?
Starling Oncology has a verified none consensus. The same dataset has an average price target of $9.00.
How far are Starling Oncology's low and high targets from the recorded price?
The low target implies +6.7%, while the high target implies +67.7%.
How many analysts are included in Starling Oncology's consensus?
The verified consensus includes 5 analysts.
How is Starling Oncology's target upside or downside calculated?
The average target of $9.00 is divided by the recorded price of $6.56, then one is subtracted to produce +37.2%. This does not guarantee a future return.
When was Starling Oncology's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.